Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Josep Lluís Acero Sánchez

Josep Lluís Acero Sánchez

Rovira i Virgili University, Spain

Title: Development of an automated system for the analysis of cell-free fetal DNA from maternal plasma for non-invasive pre-natal diagnostics

Biography

Biography: Josep Lluís Acero Sánchez

Abstract

The analysis of circulating cell-free (cf) DNA from plasma, serum or urine has the potential to serve as non-invasive approach to detect and monitor targets associated with certain diseases. In 1997, the presence of fetal DNA in the plasma and serum of pregnant women was demonstrated. This opened new perspectives in field of non-invasive pre-natal diagnostics since the analysis of cell-free fetal (cff) DNA can provide information about pregnancy related disorders (pre-eclampsia, preterm labor), chromosomal aberrations (e.g. aneuploidies), and genetic disorders (e.g. cystic fibrosis, thalassaemia, Huntington’s disease). We report on the development of an automated and integrated modular system for the isolation, amplification and detection of cffDNA from maternal plasma for non-invasive pre-natal diagnostics. The system consists of a first module for the cfDNA isolation from plasma based on silica-coated magnetic beads technology. Subsequently, the cfDNA obtained is introduced to a second module which is based on a polymeric microsystem containing a capillary electrophoresis step for the size separation of the fetal DNA from maternal DNA. Finally, the cffDNA is transferred to the amplification/detection module. This module consists of PCB (Printed Circuit Board) electrode arrays functionalized with surface immobilized primers for the multiplexed isothermal recombinase polymerase DNA amplification and electrochemical quantitative detection of specific genetic sequences. The developed technology is of generic and flexible nature allowing its facile modification to other targets of interest in clinical diagnostics and thus the developed platforms can also be exploited for analysis of circulating nucleic acids in oncology and multiple other disorders.